Web alert John Carwile, MD Sadler Clinic, 508 Medical Center Blvd., Conroe, TX 77304, USA. E-mail: jcarwile@sadler.com EditorialNotes 01 May 2007 Pages: 65 - 65
Genomic instability: The cause and effect of BCR/ABL tyrosine kinase Tomasz Skorski OriginalPaper 01 May 2007 Pages: 69 - 74
BCR-ABL-negative chronic myeloid leukemia Sonja BurgstallerAndreas ReiterNicholas C. P. Cross OriginalPaper 01 May 2007 Pages: 75 - 82
Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia Ronan SwordsYesid AlvaradoFrancis J. Giles OriginalPaper 01 May 2007 Pages: 83 - 88
Immunotherapeutic strategies in chronic myeloid leukemia Richard E. Clark OriginalPaper 01 May 2007 Pages: 89 - 94
Antibiotic prophylaxis during chemotherapy-induced neutropenia for patients with acute leukemia Sarah P. HammondLindsey R. Baden OriginalPaper 01 May 2007 Pages: 97 - 103
What role does gemtuzumab ozogamicin have in the treatment of acute myelogenous leukemia? István MolnárBayard L. Powell OriginalPaper 01 May 2007 Pages: 104 - 110
New approaches for the detection of minimal residual disease in acute myeloid leukemia Anna van RhenenBijan MoshaverGerrit Jan Schuurhuis OriginalPaper Open access 01 May 2007 Pages: 111 - 118
Role of autologous stem cell transplantation in multiple myeloma Shaji Kumar OriginalPaper 01 May 2007 Pages: 121 - 127
Current status of bortezomib in the treatment of multiple myeloma Michele Cavo OriginalPaper 01 May 2007 Pages: 128 - 137